Cadila Healthcare Gains On CLSA Upgrade

Gold Silver Reports (GSR) – Cadila Healthcare Gains On CLSA Upgrade — Shares of the Ahmedabad-based drug maker rose as much as 3.3 percent, the most in over a month, to Rs 382.55 after CLSA upgraded the stock to ‘Buy’ from ‘Underperform’ and raised its target price to Rs 450 from Rs 440.

CLSA in a note said:

✅ Improving India outlook and strong US pipeline to drive earnings.

✅ Improvement in new launches in U.S. expected in 2018.

✅ Biosimilars, vaccines and novel research products are long-term growth drivers.

✅ Cadila to look for more product deals in specialty space from current fiscal cash flows.

✅ Expect 16 percent compounded growth rate in earnings through the financial years till March 2020.

Spread the love

Neal Bhai has been involved in the Bullion and Metals markets since 1998 – he has experience in many areas of the market from researching to trading and has worked in Delhi, India. Mobile No. - 9899900589 and 9582247600

Leave a Comment